Published in Z Kardiol on August 01, 2005
Physicians' knowledge of and compliance with guidelines: an exploratory study in cardiovascular diseases. Dtsch Arztebl Int (2011) 4.18
Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000. Clin Res Cardiol (2006) 0.99
Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol (2011) 0.96
Barriers to guideline implementation and educational needs of general practitioners regarding heart failure: a qualitative study. GMS Z Med Ausbild (2012) 0.89
Management of end stage heart failure. Heart (2007) 0.88
Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol (2007) 0.87
Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective. Clin Res Cardiol (2007) 0.85
Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study. PLoS One (2012) 0.83
Telemedical support in patients with chronic heart failure: experience from different projects in Germany. Int J Telemed Appl (2010) 0.83
[Cardiac resynchronization therapy for heart failure - from experimental pacing to evidence-based therapy]. Clin Res Cardiol (2006) 0.81
[Drug treatment of chronic heart failure]. Clin Res Cardiol (2006) 0.80
[Importance of the history and the utilization of therapy guidelines in patients with arrhythmias]. Herzschrittmacherther Elektrophysiol (2007) 0.77
[Functional capacity as a criterion for patient selection--too poor or too good for CRT?]. Herzschrittmacherther Elektrophysiol (2006) 0.75
[Indication for cardiac resynchronization therapy: Consensus 2005]. Herzschrittmacherther Elektrophysiol (2006) 0.75
[Is standard-echocardiography sufficient for identification of responders?]. Herzschrittmacherther Elektrophysiol (2006) 0.75
45(th) Annual Meeting of International Society for Pediatric Neurosurgery, Denver, USA, 8-12 October, 2017. Childs Nerv Syst (2017) 0.75
[Dilated cardiomyopathy]. Herzschrittmacherther Elektrophysiol (2012) 0.75
[Outpatient rehabilitation after myocardial infarction or for heart failure]. Herz (2012) 0.75
[Heart failure update 2010 and current ESC guidelines]. Herz (2010) 0.75
Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med (2005) 20.72
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med (1996) 12.77
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 11.26
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med (1997) 10.68
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet (1999) 10.07
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med (1997) 10.02
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17
Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med (2004) 7.12
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 6.58
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med (2004) 6.55
Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med (2002) 5.74
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med (1995) 5.22
Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA (2003) 5.09
The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med (2001) 4.94
B-type natriuretic peptide in cardiovascular disease. Lancet (2003) 4.80
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation (2003) 4.63
How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. Eur Heart J (1998) 4.48
Epidemiology, aetiology, and prognosis of heart failure. Heart (2000) 4.42
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation (2003) 3.97
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol (2004) 3.58
Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med (1995) 3.56
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 3.18
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol (2001) 2.93
Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation (2003) 2.44
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 2.35
Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA (1992) 2.31
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol (2002) 2.19
Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol (2003) 2.05
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation (2001) 2.05
Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation (2002) 1.93
Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med (2001) 1.89
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet (2002) 1.79
Heart failure with preserved systolic function. A different natural history? J Am Coll Cardiol (2001) 1.65
Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA (2003) 1.64
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol (2002) 1.58
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J (1997) 1.54
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet (2003) 1.52
Predicting mortality in patients with heart failure: a pragmatic approach. Heart (2003) 1.42
Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail (2002) 1.35
Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J (2003) 1.27
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail (2001) 1.23
The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol (1995) 1.19
Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol (2002) 1.17
Recommendations for exercise training in chronic heart failure patients. Eur Heart J (2001) 1.13
The pulmonary manifestations of left heart failure. Chest (2004) 1.13
Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation (2000) 1.06
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation (1997) 1.05
Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol (2004) 0.98
The Registry of the International Society for Heart and Lung Transplantation: ninth official report--1992. J Heart Lung Transplant (1992) 0.98
Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol (2000) 0.94
Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol (1999) 0.93
Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs (2003) 0.92
Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol (2004) 0.90
The heart failure epidemic: magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol (1996) 0.80
[Guidelines for therapy of chronic heart failure. German Society of Cardiology-Heart and Cardiovascular Research]. Z Kardiol (1998) 0.78
OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization. Eur J Heart Fail (2003) 0.77
Orthopnea and inspiratory effort in chronic heart failure patients. Respir Med (2003) 0.77
Mitral valve repair in patients with end stage cardiomyopathy: who benefits? Eur J Cardiothorac Surg (2003) 0.76
Mitral valve repair as an alternative treatment for heart failure patients. Heart Fail Monit (2003) 0.75
[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers]. Dtsch Med Wochenschr (2004) 0.75
[Echocardiography diagnosis of diastolic heart failure]. Herz (2002) 0.75
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation (1993) 4.52
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation (1998) 3.99
Safety of transesophageal echocardiography. A multicenter survey of 10,419 examinations. Circulation (1991) 3.70
Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation (1992) 3.46
Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res (1993) 2.94
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J (2003) 2.78
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes]. Dtsch Med Wochenschr (2007) 2.67
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest (1999) 2.57
An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med (1991) 2.27
Cardiopulmonary auscultation: duo for strings--Opus 99. Arch Intern Med (1999) 2.26
p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J (1999) 2.14
Fragmentation of massive pulmonary embolism using a pigtail rotation catheter. Chest (1998) 2.12
Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol (2010) 2.12
Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. J Am Coll Cardiol (1996) 2.09
Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation (1999) 2.05
Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res (1994) 2.04
[The central venous catheter. Approach to the subclavian vein]. Dtsch Med Wochenschr (2007) 2.04
[Ascites paracentesis]. Dtsch Med Wochenschr (2007) 2.03
A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project. Eur Heart J (1999) 1.98
Evaluation of the SOFA score: a single-center experience of a medical intensive care unit in 303 consecutive patients with predominantly cardiovascular disorders. Sequential Organ Failure Assessment. Intensive Care Med (2000) 1.92
Refinements in stress echocardiographic techniques improve inter-institutional agreement in interpretation of dobutamine stress echocardiograms. Eur Heart J (2002) 1.87
The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart (2001) 1.86
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos (1996) 1.86
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension (2001) 1.84
[An assembly hypothesis of chromosome movement and the changes of the spindle length during anaphase I in spermatocytes of Pales ferruginea]. Chromosoma (1972) 1.80
Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. J Am Coll Cardiol (1996) 1.79
Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest (2000) 1.76
Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation (1999) 1.74
Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation (2000) 1.73
[The cardiovascular risk factor in obesity]. Dtsch Med Wochenschr (2000) 1.73
Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures. Catheter Cardiovasc Interv (1999) 1.73
Implantation of cardiac resynchronization therapy systems in the CARE-HF trial: procedural success rate and safety. Europace (2007) 1.73
The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med (2003) 1.69
Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. Int J Clin Pract (2007) 1.69
Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation (1998) 1.69
Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest (2002) 1.67
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation (1999) 1.67
Disturbed intracoronary hemodynamics in myocardial bridging: early normalization by intracoronary stent placement. Circulation (1997) 1.67
Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res (1994) 1.66
The application of methods of non-linear dynamics for the improved and predictive recognition of patients threatened by sudden cardiac death. Cardiovasc Res (1996) 1.65
Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. J Am Coll Cardiol (1998) 1.64
CT and MR evaluation of pericardial constriction: a new diagnostic and therapeutic concept. J Thorac Imaging (1993) 1.64
Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol (1999) 1.63
A prognostic computer model to predict individual outcome in interventional cardiology. The INTERVENT Project. Eur Heart J (1997) 1.61
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther (2000) 1.61
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J (2011) 1.60
Problems encountered during introduction of Gianturco coils for transcatheter occlusion of the patent arterial duct. Eur Heart J (1997) 1.59
[Adherence to guidelines in CHF therapy in Germany]. Dtsch Med Wochenschr (2005) 1.58
Attempt to quantitate relation between cardiac function and infarct size in acute myocardial infarction. Br Heart J (1974) 1.57
Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy: an echocardiographic study. Am J Cardiol (1980) 1.56
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol (2013) 1.55
Characteristics of transient outward current in human ventricular myocytes from patients with terminal heart failure. Circ Res (1993) 1.55
Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation (1995) 1.54
Non-contrast second harmonic imaging improves interobserver agreement and accuracy of dobutamine stress echocardiography in patients with impaired image quality. Heart (2000) 1.54
Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost (2003) 1.54
M-mode echocardiography overestimates left ventricular mass in patients with normal left ventricular shape: a comparative study using three-dimensional echocardiography. Eur J Echocardiogr (2003) 1.54
A novel isoform of the smooth muscle cell differentiation marker smoothelin. J Mol Med (Berl) (1999) 1.53
A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy. Eur Heart J (2001) 1.53
Simultaneous transesophageal atrial pacing and transesophageal two-dimensional echocardiography: a new method of stress echocardiography. J Am Coll Cardiol (1990) 1.52
Congenitally corrected transposition of the great arteries (L-TGA) with situs inversus totalis in adulthood: findings with magnetic resonance imaging. Magn Reson Imaging (2000) 1.52
Magnesium deficiency is associated with periodontal disease. J Dent Res (2005) 1.51
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol (2001) 1.51
Ostial renal artery stent placement for atherosclerotic renal artery stenosis in patients with coronary artery disease. Cathet Cardiovasc Diagn (1998) 1.50
Congenital quadricuspid aortic valve anomaly associated with hypertrophic non-obstructive cardiomyopathy: a case report and review of the literature. Heart (1997) 1.50
The CARE-HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end-points. Eur J Heart Fail (2001) 1.49
Infarct size estimated from serial serum creatine phosphokinase in relation to left ventricular hemodynamics. Circulation (1977) 1.48
Elective stenting of carotid artery stenosis in patients with severe coronary artery disease. Eur Heart J (1998) 1.48
MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease. Clin Pharmacol Ther (2010) 1.47
Use of low-dose ketamine and/or midazolam for pediatric cardiac catheterization. Pediatr Cardiol (2003) 1.45
ACE inhibition improves vagal reactivity in patients with heart failure. Am Heart J (1990) 1.45
Long term angiographic and clinical follow up in patients with stent implantation for symptomatic myocardial bridging. Heart (2000) 1.45
Investigation of the male pattern baldness major genetic susceptibility loci AR/EDA2R and 20p11 in female pattern hair loss. Br J Dermatol (2012) 1.44
Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation (2001) 1.43
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology (1996) 1.42
[Cardiac manifestations of muscular dystrophies]. Z Kardiol (2005) 1.42
Quantitative aspects of ouabain binding to human erythrocyte and cardiac membranes. J Physiol (1975) 1.42
[New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr (1997) 1.42
Defining the optimum upper heart rate limit during exercise: a study in pacemaker patients with heart failure. Eur Heart J (2002) 1.41
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation (2000) 1.41
Xamoterol and the failing heart. Lancet (1989) 1.41
[About science and politics]. Dtsch Med Wochenschr (2003) 1.41
Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition with quinaprilat IV: a study using [15O] water dobutamine stress positron emission tomography. J Am Coll Cardiol (1999) 1.40
[Therapy with glitazones--a risk for cardiovascular disease?]. Dtsch Med Wochenschr (2007) 1.40
[Epileptic seizures: effects on cardiac function]. Dtsch Med Wochenschr (2011) 1.40
Extent and severity of test positivity during dobutamine stress echocardiography. Influence on the predictive value for coronary artery disease. Eur Heart J (1999) 1.40
Strategies for personalized medicine-based research and implementation in the clinical workflow. Clin Pharmacol Ther (2012) 1.40
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke (2000) 1.40
Peri-operative complications following surgical closure of atrial septal defect type II in 232 patients--a baseline study. Eur Heart J (1994) 1.39
[Clinical features and current treatment of hypertensive crisis]. Dtsch Med Wochenschr (2003) 1.39